Cambridge Healthtech Institute’s 3rd Annual

Oral Peptides & Macrocyclics

bRo5 Yet Drug-Like Molecules

April 3-4, 2024

Cambridge Healthtech Institute's Oral Peptides & Macrocyclics conference continues its focus on how to discover or design beyond rule-of-five (bRo5) molecules with oral bioavailability potential: larger molecules better suited for protein-protein interaction (PPI) drug targets than typical small molecule drug candidates, yet able to penetrate cells and reach the intracellular PPI targets that are often disease culprits. This year, however, more emphasis will be placed on the emergence of oral peptides, which are usually macrocyclic or constrained, and how they are expanding the chemical space available to medicinal, computational, and synthetic chemists for finding molecules that can bind larger surfaces with more stability. Join colleagues to learn more about designing or screening newer "large small molecule" drug modalities.

Coverage will likely include:

Applications of encoded libraries for oral peptide discovery
Synthetic chemistry advances for macrocyclic peptides
AI innovations driving macrocyclic and oral peptide drug discovery
Oral peptide, macrocyclic, or constrained peptide case studies

The deadline for priority consideration is September 15, 2023.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

We hope you can join us for the 5 concurrent day-and-a-half conferences during each half of our 19th Annual Drug Discovery Chemistry event. Registering for this conference lets you also move back and forth among parallel programs to create your own agenda.

Opportunities for Participation: